NASDAQ: FRTX

Company Overview

Presentation

Making Fresh Tracks in Medicine®

January 2023

Forward-Looking Statements

  • Any statements made in this presentation relating to future financial, business, and/or research and clinical performance, conditions, plans, prospects, trends, or strategies and other such matters, including without limitation, Fresh Tracks Therapeutics Inc.'s ("FRTX") strategy; future operations; future financial position; future liquidity; future revenue; territorial focus; projected expenses; results of operations; the anticipated timing, scope, design, progress, results, and/or reporting of data of ongoing and future non-clinical and clinical trials; intellectual property rights, including the acquisition, validity, term, and enforceability of such; the expected timing and/or results of regulatory submissions and approvals; and prospects for commercializing any product candidates of Fresh Tracks or third parties, or research and/or licensing collaborations with, or actions of, its partners, including in the United States, Japan, South Korea, or any other country are forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. In addition, when or if used in this presentation, the words "may," "could," "should," "might," "anticipate," "reflects," "believe," "estimate," "expect," "intend," "plan," "predict," "potential," "will," evaluate," "advance," "excited," "aim," "strive," "help," "progress," "select," "initiate," "look forward," "promise," "provide," "commit," "best-in-class,""first-in-class," and similar expressions and their variants, as they relate to FRTX or any of FRTX's partners, or third parties, may identify forward-looking statements. Fresh Tracks cautions that these forward-looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time, often quickly, and in unanticipated ways. Important factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including without limitation, research results and data that do not meet targets, expectations, or regulatory approval requirements; ability to obtain adequate financing for product development, regulatory submissions, and any commercialization; ability to acquire, maintain, and enforce intellectual property rights; potential delays or alterations in product development, trials of any type, and regulatory submission and reviews; changes in law or policy; litigation; regulatory agency feedback or requests; supply chain disruptions; unanticipated demands on cash resources; disruptions and negative effects related to the COVID-19 pandemic and/or the conflict in Ukraine; interruptions, disruption, or inability by FRTX, its partners or third parties to obtain or supply research material, raw materials, and/or product anywhere, or secure essential services, in the world; efforts to obtain and retain adequate pricing and adequate reimbursement and other insurance coverage for Fresh Tracks' products; the outcome of FRTX's current and planned preclinical and clinical trials across its portfolio of assets; and other risks associated with developing and obtaining regulatory approval for, and commercializing, product candidates.
  • Further information on the factors and risks that could cause actual results to differ from any forward-looking statements are contained in Fresh Tracks' filings with the United States Securities and Exchange Commission, which are available at https://www.sec.gov(or at https://www.frtx.com/). The forward-looking statements represent the estimates of FRTX as of the date hereof only. Fresh Tracks specifically disclaims any duty or obligation to update forward-looking statements.

© 2023 Fresh Tracks Therapeutics, Inc. All rights reserved

2

NASDAQ: FRTX

Fresh Tracks Therapeutics, Inc.

Clinical-stage pharmaceutical company developing innovative and groundbreaking prescription therapeutics for the treatment of autoimmune, inflammatory and other debilitating diseases

Potential First-in-Class

DYRK1A Inhibitor

  • FRTX-02Phase 1 study ongoing & progressing well
  • Phase 1 SAD/MAD topline results expected early 2023
  • Broad potential for the treatment of debilitating autoimmune and inflammatory diseases

Potential First-in-Class

STING Inhibitor

  • FRTX-10preclinical development underway
  • Demonstrated strong proof- of-mechanism & promising profile in initial preclinical studies
  • Potential to treat a wide array of autoinflammatory disorders and rare interferonopathies

Cutting-Edge

Kinase Inhibitors

  • Extensive library of small molecule next-generationkinase inhibitors targeting DYRK1, LRRK2, TTK, and
    CLK
  • Opportunity to explore various autoimmune, inflammatory, neurodegenerative, and oncology diseases

Trailblazing

Leadership Team

  • Experienced leadership team with proven track record developing and launching several novel products that achieved first-in-class and/or iconic status
  • Developed sofpironium bromide, the first topical NCE for hyperhidrosis, from preclinical through successful Phase 3; Asset sold in May 2022

© 2023 Fresh Tracks Therapeutics, Inc. All rights reserved

3

TRANSFORMATIVE THERAPEUTICS

Pipeline of NCEs with First-in-Class Potential

PROGRAM

FRTX-02

Oral DYRK1A

Inhibitor

FRTX-10

Oral STING

Inhibitor

Next-Generation Kinase Inhibitors

Oral DYRK1, LRRK2, TTK & CLK Inhibitors

FRTX-03

Topical DYRK1A Inhibitor

DISCOVERY

PRECLINICAL

PHASE 1

PHASE 2

AUTOIMMUNE DISEASES: Atopic Dermatitis | Rheumatoid Arthritis | Type 1 Diabetes | Others

AUTOINFLAMMATORY DISEASES: Systemic Lupus Erythematosus | Dermatomyositis | NASH

AUTOIMMUNE, NEUROINFLAMMATORY, AND OTHER DISEASES

AUTOIMMUNE DERMATOLOGY: Atopic Dermatitis | Psoriasis | Others

PHASE 3

NEXT MILESTONE

Phase 1 SAD/MAD

Topline Results:

Early 2023

Preclinical

Development

Preclinical Characterization

Formulation

Development

© 2023 Fresh Tracks Therapeutics, Inc. All rights reserved

4

TRAILBLAZING LEADERSHIP

Executing Strategy with an Experienced Leadership Team

Our executives have developed and/or launched several novel products achieving first-in-class and/or iconic status

C H I E F E X E C U T I V E O F F I C E R

Robert Brown

C O - F O U N D E R & P R E S I D E N T

Andy Sklawer

C H I E F R & D & C H I E F O P E R A T I N G O F F I C E R

Deepak Chadha

C H I E F M E D I C A L O F F I C E R

Monica Luchi

C H I E F F I N A N C I A L O F F I C E R

Albert Marchio II

G E N E R A L C O U N S E L & C C O

David McAvoy

© 2023 Fresh Tracks Therapeutics, Inc. All rights reserved

5

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Fresh Tracks Therapeutics Inc. published this content on 04 January 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 04 January 2023 15:07:05 UTC.